Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic Profiling Identified ERCC2 E606Q Mutation in Helicase Domain Respond to Platinum-Based Neoadjuvant Therapy in Urothelial Bladder Cancer

26 Aug 2020

Abstract excerpt

Genomic profiling of tumours enables therapeutic decisions, and identifying drug-matched mutations will prolong survival and prognosis. Here, we generated a custom panel for detecting genetic alterations in 19 patients with urothelial bladder cancer. This panel targeted 71 genes associated with urological cancer. Targeted sequencing was performed on formalin-fixed paraffin-embedded tumour tissues. Paired...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Epigenetics and DNA Methylation
Share to Urinary and Genital Oncology Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32984035
DOI: 10.3389/fonc.2020.01643

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic Profiling Identified ERCC2 E606Q Mutation in Helicase Domain Respond to Platinum-Based Neoadjuvant Therapy in Urothelial Bladder CancerPMID 32984035Read ↗

ERCC2 mutations alter the genomic distribution pattern of somatic mutations and are independently prognostic in bladder cancer.Semantic proximity Read ↗

ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder CancerSemantic proximity Read ↗

Similar genetic profile in early and late stage urothelial tract cancer.Semantic proximity Read ↗

Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancerSemantic proximity Read ↗

Genetic characteristics and targeted treatments of primary bladder and urachal adenocarcinomas: a systematic review with pooled descriptive genomic analyses.Semantic proximity Read ↗

The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers.Semantic proximity Read ↗

Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients.Semantic proximity Read ↗

Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder CancerSemantic proximity Read ↗

Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapySemantic proximity Read ↗

Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomasSemantic proximity Read ↗

Identification of an <i>ERCC2</i> mutation associated mutational signature of nucleotide excision repair deficiency in targeted panel sequencing dataSemantic proximity Read ↗

Management of advanced bladder cancer in the era of targeted therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.